SG10201913215YA - Therapeutic agent for biliary tract cancer - Google Patents
Therapeutic agent for biliary tract cancerInfo
- Publication number
- SG10201913215YA SG10201913215YA SG10201913215YA SG10201913215YA SG10201913215YA SG 10201913215Y A SG10201913215Y A SG 10201913215YA SG 10201913215Y A SG10201913215Y A SG 10201913215YA SG 10201913215Y A SG10201913215Y A SG 10201913215YA SG 10201913215Y A SG10201913215Y A SG 10201913215YA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic agent
- biliary tract
- tract cancer
- cancer
- biliary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015162004 | 2015-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913215YA true SG10201913215YA (en) | 2020-02-27 |
Family
ID=58052163
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913215YA SG10201913215YA (en) | 2015-08-19 | 2016-08-17 | Therapeutic agent for biliary tract cancer |
SG11201800865WA SG11201800865WA (en) | 2015-08-19 | 2016-08-17 | Therapeutic agent for biliary tract cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201800865WA SG11201800865WA (en) | 2015-08-19 | 2016-08-17 | Therapeutic agent for biliary tract cancer |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190000829A1 (ru) |
EP (1) | EP3338778A4 (ru) |
JP (1) | JPWO2017030146A1 (ru) |
KR (1) | KR20180037953A (ru) |
CN (1) | CN107921039A (ru) |
AU (1) | AU2016308390A1 (ru) |
BR (1) | BR112018002239A2 (ru) |
CA (1) | CA2994224A1 (ru) |
IL (1) | IL257292A (ru) |
MX (1) | MX2018001439A (ru) |
RU (1) | RU2728932C2 (ru) |
SG (2) | SG10201913215YA (ru) |
WO (1) | WO2017030146A1 (ru) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1753723E (pt) * | 2004-05-21 | 2008-11-19 | Novartis Vaccines & Diagnostic | Derivados de quinolina substituída como inibidores de quinesina mitótica |
RU2448708C3 (ru) * | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
CN101616671A (zh) * | 2007-01-19 | 2009-12-30 | 卫材R&D管理有限公司 | 胰腺癌治疗用组合物 |
CA2898326C (en) * | 2013-01-18 | 2022-05-17 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
JP6637884B2 (ja) * | 2013-11-08 | 2020-01-29 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ブロモドメインおよびエクストラターミナル(bet)タンパク質インヒビターを使用するがんのための併用療法 |
-
2016
- 2016-08-17 KR KR1020187003198A patent/KR20180037953A/ko not_active Application Discontinuation
- 2016-08-17 CN CN201680044979.XA patent/CN107921039A/zh active Pending
- 2016-08-17 US US15/748,980 patent/US20190000829A1/en not_active Abandoned
- 2016-08-17 JP JP2017535551A patent/JPWO2017030146A1/ja active Pending
- 2016-08-17 CA CA2994224A patent/CA2994224A1/en not_active Abandoned
- 2016-08-17 WO PCT/JP2016/074017 patent/WO2017030146A1/ja active Application Filing
- 2016-08-17 SG SG10201913215YA patent/SG10201913215YA/en unknown
- 2016-08-17 SG SG11201800865WA patent/SG11201800865WA/en unknown
- 2016-08-17 BR BR112018002239-0A patent/BR112018002239A2/pt not_active Application Discontinuation
- 2016-08-17 EP EP16837135.9A patent/EP3338778A4/en not_active Withdrawn
- 2016-08-17 AU AU2016308390A patent/AU2016308390A1/en not_active Abandoned
- 2016-08-17 RU RU2018103737A patent/RU2728932C2/ru active
- 2016-08-17 MX MX2018001439A patent/MX2018001439A/es unknown
-
2018
- 2018-02-01 IL IL257292A patent/IL257292A/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2018103737A3 (ru) | 2019-10-11 |
EP3338778A4 (en) | 2019-04-17 |
WO2017030146A1 (ja) | 2017-02-23 |
CA2994224A1 (en) | 2017-02-23 |
RU2728932C2 (ru) | 2020-08-03 |
BR112018002239A2 (pt) | 2018-09-18 |
SG11201800865WA (en) | 2018-02-27 |
IL257292A (en) | 2018-03-29 |
JPWO2017030146A1 (ja) | 2018-06-07 |
EP3338778A1 (en) | 2018-06-27 |
KR20180037953A (ko) | 2018-04-13 |
CN107921039A (zh) | 2018-04-17 |
AU2016308390A1 (en) | 2018-02-22 |
US20190000829A1 (en) | 2019-01-03 |
MX2018001439A (es) | 2018-05-28 |
RU2018103737A (ru) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL253701A0 (en) | Medicinal material for bile duct cancer | |
PL3616720T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
IL254705B (en) | Combined treatment for cancer | |
IL250685A0 (en) | Medicinal substance induces cytotoxicity | |
IL249231A0 (en) | Pharmaceutical combinations for cancer treatment | |
IL266012A (en) | Combination therapy for c3 inhibition | |
EP3132802A4 (en) | Therapeutic agent for solid cancer | |
IL253549B (en) | Antibody-urease conjugates for therapeutic purposes | |
HUE053648T2 (hu) | Gyógyászati kombinációk rák kezelésére | |
IL258671A (en) | A therapeutic agent for breast cancer | |
IL268416A (en) | Pharmaceutical combinations for cancer treatment | |
IL270140B (en) | A therapeutic agent for blood cancer | |
ZA201707024B (en) | Cancer treatment composition | |
HK1254687A1 (zh) | 用於癌症的聯合療法 | |
IL257292A (en) | Therapeutic agent for biliary tract cancer | |
HRP20210383T8 (hr) | Kombinirana terapija za rak | |
HK1259026A1 (zh) | 用於治療癌症的抗趨除劑的局部遞送 | |
SG11201801083UA (en) | Tumor therapeutic agent | |
GB201702921D0 (en) | Therapeutic agent | |
GB201911521D0 (en) | Therapeutic agent | |
GB201516109D0 (en) | Therapeutic agent | |
GB201417819D0 (en) | Agents for cancer therapy |